RANIVA
Generic Name: Ranitidine Hydrochloride
Strength: 25mg/ml
Volume: 2ml
Therapeutic category: Anti-Ulcer; Hyper Acidity; H2 Receptor Antagonist
Description: Raniva I.V./I.M. Injection or Infusion is clear and colorless to pale yellow solution. It contains 25mg/ml of Ranitidine and it belongs to a group of medicines called Histamine H2 Antagonist.
Therapeutic Indication:
Ranitidine Injection is indicated in treatment of Duodenal Ulcer, Benign Gastric Ulcer, Post-operative Ulcer, Reflux Oesophagitis, Zollinger-Ellison Syndrome, Prophylaxis of recurrent haemorrhage from peptic ulcder, Prophylaxis of Mendelson’s syndrome.
Peadiatric population (6 months to 18 years)
- Short term treatment of peptic ulcer
- Treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease.
Dosage and Administration:
Adults (including older people)/ Adolescents (12 years and over)
Raniva Injection may be given as a slow (over 2 min) I.V. Injection of 50 mg, diluted to a volume of 20 ml, every 6 to 8 hours, an intermittent I.V. infusion at 25mg/hour for 2 hours, repeated at 6 to 8 hour intervals, an I.M. Injection of 50mg every 6 to 8 hours.
Prophylaxis of Mendelson’s Syndrome: 50 mg by I.M. or slow I.V. Injection 45 to 60 minutes before induction of general anaesthesia.
Prophylaxis of haemorrhage from stress ulceration: in seriously ill patients dose of 50 mg as a slow I.V. injection followed by a continuous intravenous infusion of 0.125-0.250 mg/kg/h may be preferred.
Children/infants (6 months to 11 years)
Ranitidine Injection may be given as a slow (over 2 mins) I.V. Injection up to a maximum of 50mg every 6 to 8 hours.
Neonates (under 1 month)
The initial dose (2.0 mg/kg or 2.5 mg/kg, maximum 50 mg) may be administered as a slow intravenous infusion over 10 minutes, either with a syringe pump followed by a 3 ml flush with normal saline over 5 min, or following dilution with normal saline to 20 ml.
Renal Impairment
Accumulation of ranitidine with resulting elevated plasma concentrations will occur in patients with severe renal impairment. It is recommended in such patients that ranitidine be administered in doses of 25mg.
Prescribing Information: PDF Download
The details of our product are included from the finalized insert available for our products.